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ABSTRACT
Background: Opioid therapy for patients with chronic nonmalignant pain remains controversial, primarily because 
of safety concerns and the potential for abuse. The objective of this study was to examine trends in opioid utilization 
for nonmalignant pain among recipients of social assistance and to explore the relation between dose of analgesic and 
mortality.
Methods: Using a cross-sectional study design, we characterized annual trends in prescriptions for and daily dose of opioid 
analgesics between 2003 and 2008 for beneficiaries (aged 15 to 64 years) of Ontario’s public drug plan. We defined moder-
ate, high and very high dose thresholds as daily doses of up to 200, 201 to 400, and more than 400 mg oral morphine (or 
equivalent), respectively. In an exploratory cohort study, we followed, over a 2-year period, patients who received at least 
one prescription for an opioid in 2004 to investigate the relation between opioid dose and opioid-related mortality. 
Results: Over the study period, opioid prescribing rates rose by 16.2%, and 180 974 individuals received nearly 1.5 mil-
lion opioid prescriptions in 2008. Also by 2008, the daily dose dispensed exceeded 200 mg morphine equivalent for 
almost a third (32.6%) of recipients of long-acting oxycodone but only 20.3% of those treated with fentanyl or other long-
acting opioids. Among patients for whom high or very high doses of opioids were dispensed in 2004, 19.3% of deaths 
during the subsequent 2 years were opioid-related, occurring at a median age of 46 years. Two-year opioid-related mor-
tality rates were 1.63 per 1000 population (95% confidence interval [CI] 1.42–1.85) among people with moderate-dose 
prescriptions, 7.92 per 1000 population (95% CI 5.25–11.49) among those with high-dose prescriptions, and 9.94 per 
1000 population (95% CI 2.78–25.12) among those with very-high-dose prescriptions.
Interpretation: Among socio-economically disadvantaged patients in Ontario, the use and dose of opioids for nonma-
lignant pain has increased substantially, driven primarily by the use of long-acting oxycodone and, to a lesser extent, 
fentanyl. The findings of our exploratory study suggested a strong association between opioid-related mortality and the 
dose of opioid dispensed.
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1 Jan. 2003 and 31 Dec. 2008. Second, we conducted an 
exploratory analysis of individuals in this group who had 
received at least one prescription for opioids in calendar 
year 2004, with the intent of characterizing the relation 
between opioid dose and the 2-year mortality rate. On-
tario residents are eligible for drug coverage if they are 
unemployed  or  disabled,  have  high  prescription  drug 
costs in relation to their net household income, receive 
home care, reside in a long-term care facility or are 65 
years of age or older. We restricted our analyses to indi-
viduals under 65 years of age who were eligible for drug 
coverage at the time of the study, because they represent 
a population of socio-economically disadvantaged indi-
viduals who are thought to be at especially high risk for 
misuse of opioids and associated harm.
12,13 
Data sources. We identified opioid treatment using the 
database of the Ontario Drug Benefit Program, which 
contains  a  detailed  record  of  all  prescription  medica-
tions dispensed to Ontario residents eligible for cover-
age. We identified exclusionary cancer diagnoses using 
the Ontario Cancer Registry, a computerized database 
of information about all Ontario residents with a new 
diagnosis of cancer and those dying of cancer. We identi-
fied palliative care services, comorbidity and health re-
source utilization using hospital admissions data from 
the Canadian Institute for Health Information Discharge 
Abstract Database and physician billing data from the 
Ontario Health Insurance Plan (OHIP) database. We ob-
tained demographic information, including date of death, 
from the Ontario Registered Persons Database, which 
contains a unique entry for each resident who has ever 
received insured health services. These databases were 
anonymously linked using 10-digit health card numbers, 
have been described extensively elsewhere
23–25 and are 
routinely used to investigate drug safety in Ontario.
26–28 
This project was approved by the Research Ethics Board 
of Sunnybrook Health Sciences Centre, Toronto. 
Identification of patients. We identified persons 15 to 
64 years of age on 31 Dec. of each year who had received 
at least one prescription for an opioid analgesic during 
the same calendar year. We excluded individuals with 
any prior diagnosis of cancer and those receiving pal-
liative care services in the 180 days preceding their first 
opioid prescription each year. A patient was deemed to 
have received palliative care if he or she had been admit-
ted to hospital with a patient service code for palliative 
care or if a treating physician had billed OHIP for any 
of the following palliative care fee codes: A945, B998, 
C945, C882, C982, K023, W872, W882, W972 or W982. 
T
  he use of opioid analgesics for the treatment 
of pain associated with cancer or end-of-life con-
ditions is widely accepted. However, the appro-
priateness of these drugs for the treatment of chronic 
nonmalignant  pain  is  the  subject  of  considerable  de-
bate.
1–5 Systematic reviews have suggested that the safe-
ty and effectiveness of long-term opioid therapy remain 
unproven,
6–8 and recent studies have yielded conflicting 
results with respect to reduction of pain and improve-
ment in quality of life and functional capacity for pa-
tients  with  chronic  nonmalignant  pain.
9–11  Further-
more, several studies have suggested a strong associa-
tion between abuse of prescription opioids and younger 
age, poverty and unemployment.
12–16
Recognizing  the  potential  for  opioid  abuse,  addic-
tion, diversion and related mortality, many jurisdictions 
have developed guidelines or implemented programs to 
promote more judicious use of these drugs.
1,2,17–21 For 
example, in 2007, the state of Washington issued guide-
lines recommending that the daily dose of opioids for 
patients with chronic nonmalignant pain should gener-
ally not exceed 120 mg of oral morphine or the equiva-
lent amount of another opioid.
20 In 2009, the American 
Pain Society and the American Academy of Pain Medi-
cine defined a high dose of opioid as more than 200 mg 
of oral morphine (or equivalent) per day,
1 on the basis of 
a review of randomized trials and observational studies. 
Recent Canadian guidelines identified 200 mg of mor-
phine equivalent as a “watchful dose,” suggesting that 
higher doses warrant frequent monitoring, along with 
careful reassessment of the pain problem and the risk 
of misuse.
21 However, only limited data are available re-
garding both the extent to which these thresholds are 
exceeded in clinical practice and the relative safety of 
such doses, particularly in vulnerable populations.
The objective of this study was to examine temporal 
trends in opioid use and dosing and any association of 
these trends with opioid-related mortality among socio-
economically disadvantaged patients with chronic non-
malignant pain. We focused particularly on OxyContin 
(Purdue  Pharma),  a  long-acting  formulation  of  oxy-
codone, because evidence suggests that the prescribing 
of opioids and opioid-related mortality increased sub-
stantially in Ontario following the introduction of this 
formulation to the provincial formulary.
22 
Methods
Study  designs.  We  performed  two  studies.  First,  we 
conducted a cross-sectional time series analysis exam-
ining annual prescription claims for opioid analgesics 
reimbursed by Ontario Public Drug Programs between Open Medicine 2011;5(1):e15
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and opioid-related deaths.
22 Although each patient was 
assigned to 1 of the 5 opioid groups annually on the basis 
of the hierarchy described above, all opioids dispensed 
for each patient contributed to the analyses. Therefore, 
a patient who switched treatment or received multiple 
opioid drugs in a given year was placed in only one ex-
posure group (based on the hierarchy in Figure 1), but 
all of the person’s opioid prescriptions were considered 
in the analyses. In a sensitivity analysis, we considered 
only the opioid or opioids specific to the treatment group 
(e.g.,  long-acting  oxycodone)  and  disregarded  concur-
rent therapy with other opioids.
Quantification of opioid use. For each of the 5 opioid 
groups, we expressed prescriptions as a rate per 1000 
eligible persons, eligibility being defined by the number 
of Ontarians between 15 and 65 years of age on 31 De-
cember of each calendar year who received any prescrip-
tion paid by Ontario Public Drug Programs during the 
same year.
For each individual who received at least one opioid 
prescription in a given calendar year, we calculated the 
mean daily dose dispensed (mg) of oral morphine, or 
equivalent, on the basis of the person’s first 90 days of 
opioid therapy. If the supply of drug dispensed for a pre-
scription in that interval extended beyond 90 days, we 
excluded the excess. The adjusted total amount of mor-
phine equivalents dispensed over the 90 days was div-
ided by 90 to obtain the mean daily dose for the period. 
Conservative  morphine  equivalence  ratios  were  based 
on guidelines developed by the Canadian National Opi-
oid Use Guideline Group (Table 1)
21 and are similar to 
those published elsewhere.
29,30 
In accordance with the guidelines,
1,21 we categorized 
patients as having received a moderate dose of opioids if 
the mean daily dose was up to 200 mg of oral morphine 
(or equivalent), a high dose if the mean daily dose was be-
tween 201 and 400 mg of oral morphine (or equivalent) 
and a very high dose if the mean daily dose was more 
than 400 mg of oral morphine (or equivalent), based on 
the first 90 days of therapy in each year. We then calcu-
lated the percentage of patients in each dose category for 
each opioid therapy group in every year.
Within  each  dose  category  of  each  opioid  therapy 
group in 2008, we ascertained demographic informa-
tion and health care utilization (i.e., number of hospital 
admissions and number of physician visits) in the past 
year. We also calculated the median daily amount (in 
milligrams of oral morphine or equivalent) of all opioids 
dispensed and of the opioid specific to the therapy group.
We examined prescriptions for codeine, morphine, oxy-
codone, hydromorphone, meperidine and transdermal 
fentanyl. We excluded prescriptions for parenteral and 
intranasal preparations of opioids and prescriptions for 
methadone, the latter because it is principally used for 
opioid addiction rather than chronic pain in Ontario. 
Each individual was assigned to 1 of 5 mutually exclu-
sive groups (Figure 1) on the basis of the characteristics of 
his or her opioid therapy over the course of each calendar 
year: long-acting oxycodone (regardless of other opioid 
therapy), transdermal fentanyl with no long-acting oxy-
codone, other long-acting opioids (with no long-acting 
oxycodone or fentanyl), immediate-release single-agent 
opioid therapy or combination products (which contain 
an  immediate-release  opioid  and  one  of  either  aceta-
minophen  or  acetylsalicylic  acid).  This  hierarchy  was 
based on the clinical impression that recipients of long-
acting oxycodone and fentanyl receive higher doses than 
recipients of other long-acting opioids, as well as on the 
nature of the formulations (single v. multiple analgesics, 
immediate  v.  long-acting)  and  recent  data  suggesting 
an association between the addition of long-acting oxy-
codone to the formulary of Ontario’s public drug plan 
All people with prescription 
dispensed for an opioid
Yes
Long-acting oxycodone 
dispensed?
No
Group 1: Long-acting 
                  oxycodone
Transdermal fentanyl 
dispensed?
Group 2: Transdermal
                  fentanyl
Yes
No
No
No Yes
Yes
Any other long-acting opioid
dispensed?
Group 3: Other long-acting
                  opiods
Immediate-release single-
agent therapy dispensed?
Group 4: Immediate-release
                  single-agent therapy                  
Group 5: Immediate-release
                  combination therapy
Figure 1: Hierarchical categorization of study participants 
according to type of opioids receivedOpen Medicine 2011;5(1):e16
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by age and sex using direct standardization methods. We 
used Statistics Canada’s 2006 Canadian population as 
the standard population for all standardized rates, and 
we approximated 95% confidence intervals (CIs) using a 
gamma interval based on the assumption that the rates 
were distributed as a weighted sum of independent Pois-
son random variables.
31 This method is considered more 
conservative than other similar methods. We used SAS 
version 9.2 statistical software (SAS Institute, Cary, NC) 
to perform all analyses.
Role of the sponsors. This study was supported by the 
Ontario Drug Policy Research Network, which is funded 
by a grant from the Ontario Ministry of Health and Long-
Term Care (MOHLTC) Drug Innovation Fund and the 
Institute for Clinical Evaluative Sciences, a nonprofit re-
search institute sponsored by the Ontario MOHLTC. The 
collection, analysis and interpretation of data, the results 
and conclusions reported in this paper, and the decision 
to submit the report for publication were the responsibil-
ity of the authors, independent from the funding sources. 
Results
Over the 6-year study period, the annual prescribing rate 
for opioids rose by 16.2%, from 1848 prescriptions per 
1000 eligible individuals in 2003 to 2148 prescriptions per 
1000 eligible individuals in 2008. Among these individ-
uals, the annual prevalence of use of long-acting opioids 
increased by 52.4%, from 12.4% to 18.9% of opioid recipi-
ents. In particular, the use of long-acting oxycodone rose 
by 142.2%, from 7471 to 18 096 people. In 2008, 180 974 
(26.4%) of 686 307 eligible social assistance beneficiaries 
received a total of 1 474 490 prescriptions for opioids, and 
approximately 1 of every 5 such prescriptions (n = 327 441 
[22.2%]) was for either long-acting oxycodone or fentanyl. 
A higher proportion of recipients of long-acting oxycodone 
were male (52%) than was the case for other opioid treat-
ment groups (range 38% to 47%; Table 2). 
Patterns of use of opioid analgesics. Over the study 
period, prescription rates in the long-acting oxycodone 
group more than doubled, from 331 per 1000 population 
in 2003 to 675 per 1000 population in 2008, whereas pre-
scribing of combination analgesic therapy decreased by 
14% (from 969 to 831 per 1000 population) and prescrip-
tion rates in all other opioid groups remained stable (Fig-
ure 2). By 2008, prescribing for long-acting oxycodone 
accounted for nearly one-fifth (n = 277 024 of 1 474 490; 
18.8%) of all opioid prescriptions and more than half   
(n = 277 024 of 526 563; 52.6%) of all long-acting opioid 
prescriptions. 
Opioid dose and risk of death. We conducted an ex-
ploratory cohort study to examine the risk of opioid-re-
lated death among all socio-economically disadvantaged 
patients aged 15 to 64 years who received a prescription 
for an opioid in 2004. We followed each patient for a 
maximum of 2 years from the date of the initial opioid 
prescription to the date of death or the end of follow-up 
(i.e., 2 years), as applicable. Using the records of the Of-
fice of the Chief Coroner of Ontario, we identified opi-
oid-related deaths as deaths caused by a combination of 
drugs including at least one opioid, or death in which 
a toxicological analysis revealed opioid concentrations 
high enough to cause death. This method is described 
in more detail elsewhere.
22 We defined the period of an-
alysis to exclude files from 2007 onward, to avoid cases 
in which the coroner’s data were incomplete. For each 
opioid dose category (moderate, high and very high), we 
calculated  age-  and  sex-standardized  mortality  rates 
over the subsequent 2 years, using the 2006 Ontario 
population  as  the  standard  population.  Each  patient 
was assigned to an opioid dose category according to the 
medication received during the first 90 days of therapy, 
as  described  above.  We  repeated  the  analysis  for  the 
risk of all-cause mortality, where deaths from any cause 
were identified from the Registered Persons Data Base. 
For comparison, we also calculated 2-year age- and sex-
standardized all-cause mortality rates for the Ontario 
population aged 15 to 64 years on 1 Jan. 2004 who did 
not receive an opioid prescription in 2004.
Statistical analysis. We calculated basic descriptive sta-
tistics for the cross-sectional analyses: mean and stan-
dard deviation for normally distributed data and median 
and interquartile range for skewed data. In the explora-
tory cohort study, we standardized the mortality rates 
Table 1: Morphine equivalents for oral opioid analgesics* 
Opioid Ratio (opioid to morphine)
Codeine     1 : 0.15
Oxycodone     1 :1.5
Hydromorphone     1 : 5
Meperidine     1 : 0.1
Transdermal fentanyl
  25 µg/h     1 : 97
  50 µg/h     1: 202
  75 µg/h     1: 292
100 µg/h     1: 382
*Data source: National Opioid Use Guideline Group, Canadian Guideline 
for Safe and E￿  ective Use of Opioids for Chronic Non-Cancer Pain.21 
Appendix B-8.1, Table 1 (equivalence to oral morphine) and Table 2 
(equivalence between oral morphine and transdermal fentanyl). The  
midpoint of the fentanyl ranges was used in our conversions.  Open Medicine 2011;5(1):e17
Research                                                                                                                                     Gomes et al.
high doses) are shown in Figure 4. Although high doses 
of  immediate-release  opioids  were  uncommon,  20.5% 
of patients with a prescription for a long-acting opioid 
received high-dose or very-high-dose therapy in 2003. 
This proportion increased to 26.8% of patients by 2008. 
Among  patients  treated  with  very-high-dose  opioids, 
two-thirds (66.2%) received long-acting oxycodone.
By 2008, a third of all patients receiving long-acting 
oxycodone (n = 5903 [32.6%] of 18 096) received a high 
or very high dose. Almost half of these (n = 2594 [43.9%]) 
received a very high dose, and the median daily opioid 
dose equivalent was 613 mg of oral morphine (Table 2). 
The median dose was unchanged in a sensitivity analy-
sis that discounted all other opioids dispensed to these 
patients, which indicates that the high dose was driven 
primarily by prescriptions for long-acting oxycodone. 
Between 2003 and 2008, the mean daily dose of opioid 
dispensed to each person remained relatively constant 
for all but two of the opioid therapy groups, the excep-
tions being patients with prescriptions for long-acting 
oxycodone  and  those  with  prescriptions  for  fentanyl. 
For patients receiving long-acting oxycodone, the mean 
daily dose rose by 27.4% (from 175 to 223 mg oral mor-
phine equivalent) and for those receiving transdermal 
fentanyl, the mean daily dose rose by 14.2% (from 134 to 
153 mg oral morphine equivalent) (Figure 3). By 2008, 
the mean daily dose of opioids dispensed in the entire 
cohort was 42.4 mg oral morphine (or equivalent).
High-dose  and  very-high-dose  opioid  therapy.  The 
trends  in  prescribing  of  daily  opioid  doses  that  ex-
ceeded current clinical guidelines (i.e., high and very 
Table 2: Characteristics of patients who received prescriptions for opioids in 2008, by opioid group and dose
Type and dose of opioid n
Age, yr, 
mean (SD)
Sex, no. (%) 
male
Dose, mg/day, median (IQR) 
Type of health resource; utilization 
in past year, mean (SD)
All opioids Specifi  c opioid Hospital admissions Physician visits 
Long-acting oxycodone
Moderate dose 12 193 46.7 (10.4) 6 024 (49) 75 (40–122) 61 (30–117) 0.3 (0.9) 29.1 (29.8)
High dose 3 309 46.1 (9.3) 1 786 (54) 270 (235–327) 272 (240–340) 0.3 (0.8) 28.7 (27.1)
Very high dose 2 594 45.5 (8.8) 1 548 (60) 613 (489–910) 613 (488–894) 0.2 (0.7) 31.7 (28.3)
All doses 18 096 46.4 (10.0) 9 358 (52) 121 (58–257) 97 (40–232) 0.3 (0.8) 29.4 (29.1)
Transdermal fentanyl*
Moderate dose 3 480 49.1 (10.0) 1 350 (39) 81 (42–125) 67 (32–114) 0.5 (1.2) 37.2 (41.3)
High dose 631 49.0 (9.1) 273 (43) 263 (226–314) 260 (225–310) 0.5 (1.1) 34.5 (37.9)
Very high dose 280 47.3 (8.3) 129 (46) 569 (461–774) 535 (441–628) 0.6 (1.4) 42.8 (49.0)
All doses 4 391 49.0 (9.8) 1 752 (40) 101 (52–177) 79 (34–138) 0.5 (1.2) 37.2 (41.4)
Other long-acting opioids†
Moderate dose 9 362 49.2 (9.8) 4 280 (46) 52 (27–93) 42 (20–88) 0.4 (1.0) 29.5 (34.1)
High dose 1 385 49.1 (8.7) 713 (51) 271 (232–322) 276 (237–326) 0.3 (0.9) 28.6 (32.1)
Very high dose 974 49.0 (8.2) 523 (54) 619 (480–903) 607 (479–870) 0.4 (1.2) 27.7 (31.7)
All doses 11 721 49.2 (9.5) 5 516 (47) 68 (31–163) 59 (23–137) 0.4 (1.0) 29.2 (33.7)
Immediate-release single-agent opioid therapy
Moderate dose 13 735 44.9 (12.8) 5 197 (38) 3 (1–10) 2 (1–6) 0.4 (0.9) 28.0 (35.9)
High dose 95 47.9 (8.1) 47 (49) 290 (230–331) 284 (230–345) 0.5 (1.2) 33.7 (33.7)
Very high dose 73 47.2 (8.8) 32 (44) 656 (466–882) 662 (464–907) 0.5 (0.9) 33.5 (26.3)
All doses 13 903 45.0 (12.8) 5 276 (38) 3 (2–10) 2 (1–6) 0.4 (0.9) 28.0 (35.8)
Immediate-release combination opioid therapy
Moderate dose 132 858 44.0 (13.0) 58 138 (44) 3 (2–8) 3 (2–8) 0.2 (0.6) 18.8 (21.4)
High dose ≤ 5** NA NA NA NA NA NA
Very high dose 0 NA NA NA NA NA NA
All doses 132 863 44.0 (13.0) 58 140 (44) 3 (2-8) 3 (2-8) 0.2 (0.6) 18.8 (21.4)
SD = standard deviation, IQR = interquartile range, NA = not applicable.
 * No long-acting oxycodone.
† No long-acting oxycodone or transdermal fentanyl.
**Cell sizes less than or equal to 5 are suppressed for privacy reasons.Open Medicine 2011;5(1):e18
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study (Figure 5), 3733 (2.4%) died from any cause with-
in 2 years of the index prescription. On average, people 
who died from any cause were followed for 0.94 years 
(standard deviation 0.61 years). The Office of the Chief 
Coroner for Ontario classified 302 of these deaths (8.1%) 
as opioid-related (Table 3), including nearly 1 of every 5 
deaths (19.3%) among patients who received high or very 
high doses of opioids. The median age of the patients was 
46 years, and oxycodone, fentanyl and morphine were 
involved in 39.2%, 21.6% and 39.2% of the deaths, re-
spectively. A minority (n = 45; 15.0%) of the deaths were 
confirmed suicides, and the 3 opioids most frequently 
involved in suicides were oxycodone (n = 24; 53.3%), co-
deine (n = 19; 42.2%) and morphine (n = 12; 26.7%).
Among Ontarians aged 15 to 64 years who were not 
treated with opioids in 2004 (n = 8 494 498), the 2-year 
age- and sex-standardized rate of death from any cause 
Between 2003 and 2008, the percentage of patients 
who received fentanyl with prescriptions for high or very 
high daily doses rose by 17.6% (from 17.6% to 20.7%). In 
contrast, there was no appreciable change (from 19.7% 
to 20.1%) in the percentage of patients receiving other 
long-acting opioids such as morphine and hydromorph-
one. In 2008, opioid dose patterns were similar between 
these two groups (users of fentanyl and other long-act-
ing opioids). A combined total of 3270 (20.3% of 16 112 
patients) received a high or very high dose, and over 
one-third of these (n = 1254 [38.3%]) received a very 
high dose. 
Opioid-related mortality. A total of 4 370 565 prescrip-
tions for opioids were dispensed through the Ontario 
public drug plan in 2004. Of the 154 411 individuals 
who met the inclusion criteria for our exploratory cohort 
Figure 2: Opioid dispensing 
rates, by opioid therapy group, 
2003–2008
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Figure 3: Estimated mean daily 
dose of opioid medication  
dispensed (as mg oral morphine 
or equivalent), by opioid therapy 
group, 2003–2008
Transdermal fentanyl (no long-acting oxycodone)
Long-acting oxycodone
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oxycodone  and,  to  a  lesser  extent,  fentanyl.  By  2008, 
roughly 1 of every 3 patients with a prescription for long-
acting oxycodone received a mean daily dose exceeding 
current clinical guidelines.
1,21 This result suggests that 
clinicians may not fully appreciate the analgesic potency 
of oxycodone, which is roughly 1.5 to 2 times more po-
tent than morphine and 10 to 20 times more potent than 
codeine.
32 Moreover, our exploratory analysis suggested 
that  all-cause  mortality  rates  may  be  associated  with 
opioid dose, given that the all-cause mortality rate was 
more than 10 times higher among patients who received 
very high daily doses of opioids than among Ontarians 
without prescriptions for opioids. Although it might be 
argued  that  users  of  opioids  are  inherently  different 
from  non-users  and  are  more  likely  to  die  regardless 
of  their  opioid  use,  we  observed  much  greater  differ-
ences in dose-related mortality for opioid-related deaths 
than for all-cause mortality. More specifically, relative 
to moderate doses of opioids, high and very high daily 
doses were associated with double the all-cause mortal-
ity rate but 5 to 6 times the opioid-related mortality rate. 
This differential in the relative change in opioid-related 
mortality  with  dose  supports  a  direct  association  be-
tween opioid dose and opioid-related mortality, although 
was  4.00  (95%  CI  3.95–4.04)  per  1000  population 
(Table 3). In contrast, the rate was 20.05 (95% CI 19.38–
20.73) per 1000 population among drug plan benefici-
aries with a prescription for an opioid. When stratified 
by dose group, the age- and sex-standardized all-cause 
mortality rates were considerably higher among patients 
with high-dose prescriptions (42.24 per 1000, 95% CI 
35.34–50.08) and very-high-dose prescriptions (44.93 
per 1000, 95% CI 32.42–60.67) than among those with 
moderate-dose prescriptions (19.28 per 1000, 95% CI 
18.61–19.97).  The  opioid-related  mortality  rate  was 
slightly  higher  among  patients  with  prescriptions  for 
very high doses of opioids (9.94 per 1000 population, 
95% CI 2.78–25.12) than among those with prescrip-
tions for high doses (7.92 per 1000 population, 95% CI 
5.25–11.49). Both of these rates were far higher than the 
rate among patients who received moderate doses (1.63 
per 1000 population, 95% CI 1.42–1.85).
Interpretation
Among Ontarians eligible for public funding of prescrip-
tion drugs, the use of high and very high doses of opi-
oids increased substantially between 2003 and 2008, 
largely because of increased prescribing of long-acting 
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Figure 4: Percentage of participants 
with a prescription for high or very 
high doses of oral morphine (or 
equivalent), by year and opioid group. 
A: High-dose therapy (201–400 mg/
day of oral morphine or equivalent). 
B: Very-high-dose therapy (> 400 mg/
day of oral morphine or equivalent). 
Note: Data for immediate-release 
combination therapy were excluded 
from this analysis because of the small 
number of participants in this group.Open Medicine 2011;5(1):e20
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for the treatment of short- and long-term pain, despite 
the  fact  that  it  is  roughly  10  times  more  potent  than 
codeine.
21
Dunn et al.,
32 in a recent investigation of the relation 
between prescription of opioids and overdose, calculated 
a mean daily opioid dose of 13.3 mg (morphine equiva-
lents), which is substantially lower than the mean daily 
dose that we observed (42.4 mg morphine equivalents) 
in the study reported here. Dunn et al. conducted their 
study in the state of Washington, where opioid guidelines 
were first published.
20 The study involved members of a 
unique Group Health Cooperative, among whom there 
were only 6 deaths.
32 Therefore, the differences between 
our findings and those of Dunn et al. may reflect differ-
ences  in  setting  and  study  population.  Although  both 
studies  described  a  dose–response  relation  between 
prescribing of opioids and risk of opioid-related death, 
our findings can more readily be generalized to socio-
economically disadvantaged individuals, a group at es-
pecially high risk of opioid abuse.
12,13
Some limitations of our work merit emphasis. First, 
we were unable to determine the indications for or ap-
propriateness  of  opioid  therapy.  However,  the  appro-
priateness of opioid therapy for chronic nonmalignant 
pain  is  itself  controversial,  and  whether  the  prescrip-
tions were appropriate would have little or no bearing on 
our observations regarding mortality. Second, although 
the classification of opioid-related deaths identified in 
data from the coroner’s office was highly specific, some 
opioid-related deaths may have escaped detection. This 
type of error would lead to underestimation of opioid-re-
lated deaths in our analysis. Furthermore, our approach 
to defining opioid dosage (based on the first 90 days of 
opioid therapy in each year) and our use of conserva-
tive morphine equivalence ratios may have resulted in 
an underestimate of the number of people who received 
high  or  very  high  doses  of  opioid  therapy  for  at  least 
some part of each year. Third, the claims data that we 
used did not identify prescriptions for which the patient 
further  research  is  needed  to  better  understand  this 
phenomenon.
We found that between 2003 and 2008, prescription 
rates for immediate-release opioid combination products 
decreased by 138 prescriptions per 1000 eligible people, 
while the corresponding rate for long-acting oxycodone 
prescriptions increased by more than twice this amount 
(344  prescriptions  per  1000  eligible  population).  We 
speculate that this difference reflects, to some extent, 
a shift from the prescribing of codeine–acetaminophen 
combination products to long-acting oxycodone.
22 Long-
acting  oxycodone  has  been  aggressively  marketed  to 
primary care physicians and became a popular option 
All opioids dispensed in 2004 
to people aged ≥ 15
 n = 4 370 565
n = 2 697 979
Exclude methadone prescriptions
n = 2 286 228
Exclude prescriptions where 
person had prior cancer diagnosis 
or palliative care in past 180 days
n = 450 421
Final cohort
n = 154 441
Keep only fi  rst prescription for 
each person (cohort entry date)
Exclude all people aged ≥ 65 
at end of accrual period 
(31 Dec. 2004)
Figure 5: Exclusion criteria applied in cohort study of opioid-relat-
ed mortality for patients with opioids dispensed in 2004. *The first 
prescription for each patient defined the person’s date of entry 
into the cohort
Table 3: Mortality rates by opioid dose
Death from any cause Opioid-related death
Dose group No. of eligible patients  No. of deaths Mortality rate  (95% CI)* No. of deaths Mortality rate  (95% CI)*
Reference population    † 8 494 498 31 840 4.00 (3.95–4.04) NA NA
All opioid users 154 411 3 733 20.05 (19.38–20.73)  302 1.86 (1.64–2.10) 
Moderate dose 149 220 3 469 19.28 (18.61–19.97) 251 1.63 (1.42–1.85)
High dose 3 063 160 42.24 (35.34–50.08) 33 7.92 (5.25–11.49)
Very high dose 2 128 104 44.93 (32.42–60.67) 18 9.94 (2.78–25.12)
CI = confi  dence interval, NA = not applicable.
*Age- and sex-adjusted mortality rate, per 1000 population, with 2006 Canadian population (Statistics Canada) as standard population.
†All Ontario residents aged 15 to 64 years who were eligible for publicly funded health care services on 1Jan. 2004. Open Medicine 2011;5(1):e21
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non-cancer pain: systematic review of efficacy and safety. Pain 
2004;112(3)372–380.
5.  Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for 
chronic noncancer pain: a meta-analysis of effectiveness and side 
effects. CMAJ 2006;174(11)1589–1594.
6.  Chou R, Clark E, Helfand M. Comparative efficacy and safety of 
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review. J Pain Symptom Manage 2003;28(5)1026–1048.
7.  Martell BA, O’Connor PG, Kerns RD, Becker WC, Morales KH, 
Kosten TR, et al. Systematic review: opioid treatment for chronic 
back pain: prevalence, efficacy, and association with addiction. 
Ann Intern Med 2007;146(2)116–127.
8.  Noble  M,  Treadwell  JR,  Tregear  SJ,  Coates  VH,  Wiffen  PJ, 
Akafomo  C,  et  al.  Long-term  opioid  management  for  chron-
ic  noncancer  pain.  Cochrane  Database  Syst  Rev  2010  Jan 
20;(1):CD006605.
9.  Eriksen J, Sjøgren P, Bruera E, Ekholm O, Rasmussen NK. Critic-
al issues on opioids in chronic non-cancer pain: an epidemio-
logical study. Pain 2006;125(1–2):172–179.
10.  Wallace M, Moulin DE, Rauck RL, Khanna S, Tudor IC, Skowron-
ski R, et al. Long-term safety, tolerability, and efficacy of OROS 
hydromorphone in patients with chronic pain. J Opioid Manag 
2009;5(2):97–105.
11.  Trescot AM, Glaser SE, Hansen H, Benyamin R, Patel S, Manchik-
anti L. Effectiveness of opioids in the treatment of chronic non-
cancer pain. Pain Physician 2008;11(2 Suppl):S181–200.
12.  Spiller  H,  Lorenz  DJ,  Bailey  EJ,  Dart  RC.  Epidemiological 
trends in abuse and misuse of prescription opioids. J Addict Dis 
2009;28(2):130–136.
13.  Boyd CJ, Teter CJ, West BT, Morales M, McCabe SE. Non-medical 
use of prescription analgesics: a three-year national longitudinal 
study. J Addict Dis 2009;28(3):232–242.
14. Sung HE, Richter L, Vaughan R, Johnson PB, Thom B. Nonmed-
ical use of prescription opioids among teenagers in the United 
States: trends and correlates. J Adolesc Health 2005;37(1):44–51.
15.  Hall AJ, Logan JE, Toblin RL, Kaplan JA, Kraner JC, Bixler D, et 
al. Patterns of abuse among unintentional pharmaceutical over-
dose fatalities. JAMA 2008;300(22):2613–2620.
16.  Ives TJ, Chelminski PR, Hammett-Stabler CA, Malone RM, Per-
hac JS, Potisek NM, et al. Predictors of opioid misuse in patients 
with chronic pain: a prospective cohort study. BMC Health Serv 
Res 2006;6:46.
17.  British Pain Society. Recommendations for the appropriate use 
of opioids for persistent non-cancer pain. London (UK): The So-
ciety; 2004. 
18.  Jovey RD, Ennis J, Gardner-Nix J, Goldman B, Hays H, Lynch 
M, et al. Use of opioid analgesics for the treatment of chronic 
noncancer  pain  –  a  consensus  statement  and  guidelines  from 
the Canadian Pain Society, 2002. Pain Res Manag 2003;8 Suppl 
A:3–28.
19.  Bacovsky R, Maclure M, Nguyen A, Lopatka H, Regier L, Bugden 
S,  et  al.  Canadian  Academic  Detailing  Collaboration:  evaluat-
ing processes and outcomes of academic detailing. Can Pharm 
J 2006;54–7.
20. Washington State. Washington State Agency Medical Directors’ 
Group.  Interagency  Guideline  on  Opioid  Dosing  for  Chronic 
Non-cancer Pain: an educational pilot to improve care and safe-
ty with opioid treatment. 2007. Olympia (WA): The Group.
21.  National Opioid Use Guideline Group. Canadian Guideline for 
Safe and Effective Use of Opioids for Chronic Non-Cancer Pain.   
paid out-of-pocket, nor did it identify drugs obtained 
through illicit means. Finally, although we adjusted for 
age and sex in our mortality analysis, we did not control 
for potential confounding variables such as comorbidity 
and past history of addiction, nor did our analysis reflect 
changes in opioid dose during follow-up. However, we 
believe it unlikely that the strong dose–response rela-
tion we observed could be explained entirely by residual 
confounding. 
In  summary,  in  a  large  cohort  of  social  assistance 
recipients aged 15 to 64 years, more than a quarter re-
ceived at least one opioid prescription in 2008, and al-
most a third of those with a prescription for long-acting 
oxycodone received mean daily doses of opioids higher 
than recommended by current clinical guidelines. Al-
most  1%  of  patients  with  prescriptions  for  very  high 
doses of opioids (> 400 mg morphine equivalent) died 
from opioid-related causes over a 2-year period.
Safety concerns regarding the use and misuse of opi-
oid analgesics, particularly within younger and lower-
income populations, are becoming widely appreciated 
by the public and medical communities alike.
22,34,34 Our 
findings highlight the widespread prescription of very 
high  doses  of  opioid  analgesics,  particularly  among 
users of long-acting oxycodone, and indicate a relation 
between opioid dose and opioid-related mortality. These 
results suggest a need for greater awareness of opioid 
prescribing guidelines, along with a better appreciation 
of the potency and potential hazards of long-acting opi-
oids in general and long-acting oxycodone in particular. 
Programs to educate physicians and pharmacists about 
opioid safety and appropriate dosing, as well as initia-
tives that allow real-time monitoring of medication use, 
may help in addressing these risks.
2,19,35–37 
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